- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2005.
- Why 4/10
- NAGLAZYME is an already-approved, marketed drug with no pending PDUFA date, no upcoming pivotal readout, and no scheduled regulatory decision. As a mature commercial product in BioMarin's diversified portfolio, it lacks a hard binary catalyst in the next 12 months, capping the impact score at 4.
NAGLAZYME is a mature, approved product with no pending binary catalysts. The next meaningful event for BioMarin overall is the Q4 2026 earnings report (late February 2027), where NAGLAZYME's steady-state revenue trajectory and any biosimilar entry updates will be visible. For this specific drug, watch for any biosimilar development announcements or label updates, but neither is currently scheduled.
Price Chart
Executive Summary
NAGLAZYME (galsulfase) is an FDA-approved enzyme replacement therapy for the ultra-rare genetic disorder MPS VI (Maroteaux-Lamy syndrome), developed and marketed by BioMarin Pharmaceutical (NASDAQ: BMRN). Approved in May 2005, it remains the only approved treatment for this indication. The drug generated $485.4 million in 2025 revenue (about 15% of BioMarin's total), though Q3 2026 revenue dipped 11.5% year-over-year to $108 million due to timing of large international orders. With no pending regulatory catalysts, no scheduled pivotal readouts, and no biosimilar competition yet on the market despite expired exclusivity, NAGLAZYME is a stable but mature commercial asset within BioMarin's now-larger and more diversified portfolio following the $4.8 billion Amicus Therapeutics acquisition.
How It Works
NAGLAZYME is an enzyme replacement therapy for patients with MPS VI (Maroteaux-Lamy syndrome), a rare genetic disorder where the body lacks an enzyme needed to break down certain complex sugars (GAGs). The drug is a manufactured version of the missing human enzyme, given as a weekly intravenous infusion, that helps break down these accumulated sugars to improve walking and stair-climbing capacity.
Trial Status
NAGLAZYME was approved by the FDA on May 31, 2005, based on a 24-week Phase 3 study in 39 MPS VI patients that showed improvements in walking and stair-climbing capacity. It is a fully commercialized product with no active pivotal trials for new indications.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalysts for NAGLAZYME specifically. The drug is a mature commercial product with no pending regulatory decisions or pivotal readouts.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report